News & analysis on the clinical development and manufacture of large molecule drugs
Oxford Biomedica, Roch Doliveux
By Ben Hargreaves
- Last updated on
Oxford Biomedica appoints Roch Doliveux as its non-executive chairman, effective as of today. The decision was taken after Lorenzo Tallarigo, the current holder of the position, informed the company that he would be retiring from the board.
Doliveux is the current chairman of Pierre Fabre and is also a non-executive director at both Stryker Corporation and UCB – at the latter company, he acted as CEO for ten years and also held a position as head of its pharma division.
Doliveux joins the team at Oxford Biomedica as the company plays a leading role in ensuring that AstraZeneca is able to produce enough doses of its vaccine for the novel coronavirus. This led to the decision earlier this month to add two additional manufacturing suites to its capacity.
As well as aiding the scale up of COVID-19 vaccines, Oxford Biomedica is also working in the rapidly developing cell and gene therapy area, which saw it seal a deal with Bristol Myers Squibb to support the development of CAR-T therapies.